Rapidly Progressive Idiopathic Pulmonary Arterial Hypertension in a Paediatric Patient Treated with Lung Transplantation
Related Experiment Video
Updated: Jul 12, 2025

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP
Published on: February 14, 2022
Filip Baszkowski1, Weronika Pelczar-Płachta1, Nikola Pempera1
1Department of Pediatric Cardiology, Poznan University of Medical Sciences, 60-572 Poznan, Poland.
Insights
This case study highlights the challenges in diagnosing and treating pediatric idiopathic pulmonary arterial hypertension (IPAH). Early symptom recognition and intensive treatment are crucial for better outcomes in children with IPAH.
Area of Science:
- Pediatric Cardiology
- Pulmonology
- Rare Diseases
Background:
- Pulmonary arterial hypertension (PAH) is a rare, heterogeneous disorder in children, often linked to congenital heart disease.
- Managing pediatric idiopathic PAH (IPAH) is challenging due to limited comparative data and reliance on adult studies and expert experience.
Purpose of the Study:
- To present a case of a 9-year-old girl with IPAH, detailing her treatment journey.
- To emphasize the importance of early symptom identification and prompt, intensive treatment in pediatric PAH.
- To share insights on diagnostic and treatment approaches for challenging pediatric cases.
Main Methods:
- The case involved a 9-year-old girl diagnosed with IPAH after a prolonged diagnostic process.
- Treatment included pharmacotherapy with treprostinil, featuring rapid dose escalation similar to adult protocols.
- The patient ultimately underwent bilateral lung transplantation.
Main Results:
- The patient showed a significant response to treprostinil therapy.
- Rapid dose escalation, mirroring adult treatment, was employed.
- The case underscores the complexity of diagnosing and managing pediatric IPAH.
Conclusions:
- Diagnosis of pediatric PAH can be lengthy due to non-specific symptoms, necessitating thorough differential diagnosis.
- Treatment initiation for pediatric IPAH is often individualized due to limited evidence.
- This case illustrates the potential utility of intensive treatment strategies and diagnostic methods in complex pediatric cases.
Abstract:
Pulmonary arterial hypertension (PAH) is a rare heterogeneous disorder in the paediatric population which is mostly associated with congenital heart disease. The management of paediatric idiopathic PAH (IPAH) is difficult due to insufficient comparative data and depends on the results of evidence-based adult studies with several pulmonary vasodilators, as well as the clinical experiences of paediatric experts. Our aim was to present the case of a 9-year-old girl who underwent several methods of treatment, including pharmacotherapy with a significant reaction to treprostinil, as well as bilateral lung transplantation. The patient's treatment was distinguished by the fact that the dose escalation was as rapid as that observed in the adult population. Due to the limited current evidence and knowledge, the initiation of treatment for these patients remains an individual choice. On the grounds of the number of non-specific symptoms, the diagnosis of this patient was a long process and based mainly on the differential diagnosis. The purpose of this paper is to study this example in order to highlight the importance of early symptoms and the quick implementation of intensive treatment. The applied methods may be useful in doubtful diagnosis processes and treatment procedures in the paediatric population.
More Related Videos
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
11:20A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position
Published on: April 1, 2022
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...